2025 Q4 -tulosraportti
Vain PDF
38 päivää sitten
Tarjoustasot
Oslo Børs
Määrä
Osto
-
Myynti
Määrä
-
Viimeisimmät kaupat
| Aika | Hinta | Määrä | Ostaja | Myyjä |
|---|---|---|---|---|
| 4 953 | - | - | ||
| 7 618 | - | - | ||
| 784 | - | - | ||
| 357 | - | - | ||
| 33 323 | - | - |
Huomioi, että vaikka osakkeisiin säästäminen on pitkällä aikavälillä tuottanut hyvin, tulevasta tuotosta ei ole takeita. On olemassa riski, että et saa sijoittamiasi varoja takaisin.
Välittäjätilasto
Dataa ei löytynyt
Yhtiötapahtumat
Datan lähde: FactSet, Quartr| Seuraava tapahtuma | |
|---|---|
2026 Q2 -tulosraportti 31.8. |
| Menneet tapahtumat | ||
|---|---|---|
2025 Q4 -tulosraportti 15.4. | ||
2025 Q2 -tulosraportti 28.8.2025 | ||
2024 Q4 -tulosraportti 10.4.2025 | ||
2024 Q2 -tulosraportti 29.8.2024 | ||
2023 Q4 -tulosraportti 25.4.2024 |
Asiakkaat katsoivat myös
Foorumi
Liity keskusteluun Nordnet Socialissa
Kirjaudu
·56 min sittenSomething I've been wondering about is that there are no recommendations from the analysts on the platform, does anyone have a thought about that?
·2 t sittenThe news is positive because the new patent application to the EPO concerns a genetic component that, according to Circio, increases the efficiency of circVec-based circRNA production by approx. 4 times. The company believes the technology can improve gene expression in gene therapy, among other things through more efficient use of AAV-based delivery systems. This is positive because patent/IP is extremely important in biotech. If Circio actually gets protection around a key component in circVec, it can strengthen their negotiating position against larger pharmaceutical companies. What seems most interesting right now is not just the patent news in isolation, but the combination of several potential triggers such as a new EPO application + planned global PCT application that can give the market more faith in the technology. Circio has announced that a feasibility study with a large global pharmaceutical company is moving on to in vivo testing. That is a more important trigger than just the patent news. They raised approx. NOK 68.6 million in Q1 2026 and had NOK 42 million in cash as of March 31, 2026. The company itself states that they are financed until at least 2030, which reduces short-term fear of equity issues, although biotech can always need more money later. The big point the market is probably following now is the warrants. Circio has 67,680,945 warrants with an exercise price of NOK 8.2508, with an exercise period from May 26 to June 9, 2026. Since the share is trading above the strike level, this can lead to both increased volatility and potential dilution, while also being able to provide the company with new capital. The next few weeks could be extra important for the development of the case. It will be particularly interesting to follow any partner news, results from in vivo testing, new patent updates, and upcoming webcast/presentation points from the company. At the same time, it is important to be aware of the risk factors around the warrant period, including possible selling pressure if many choose to exercise their warrants, any signals of new equity issues, and how volume and market interest develop.
·3 min sittenWhat do you think the price will go higher this period warrants the shares can be bought? No one will buy these shares if the price doesn't become much higher than where we are now because then the risk or the price isn't worth them so if Erik and the gang want us to buy these warrants the price must rise or they won't get this warrants money
·2 t sittenCIRCIO IS A SMALL FISH. THAT IS THE POINT. 🧬🔬 Market cap today: approx. 2 billion NOK. That is approximately 185 million dollars. Let that sink in. A company with technology that shows 60x better expression than conventional AAV. That has Big Pharma involved in the in vivo study. That has Acuitas – the partners behind the Pfizer vaccine – on the team. That presented at the world's largest gene therapy conference. That operates in a field where Big Pharma has spent 14+ billion dollars on acquisitions in the last year. Valued at 185 million dollars. A single licensing agreement could be larger than the entire market cap. That's not a boast. That's mathematics. And here's what people forget: this is normally not available to you and me. Orna, Orbital, Capstan – all private. All bought for billions. No ordinary shareholders got to participate. Circio is the exception. Is there risk? Absolutely. This is preclinical biotech. But risk alone means nothing without context. Risk in a field where Big Pharma is desperately buying platforms. With technology that is starting to show mechanism. With partner-validated in vivo progress. With multiple shots on goal – AAV, LNP, CAR-T, heart, eye, CNS. A 10x from here is not a dream. It's a scenario that actually has a logical path there. We know what we own. ♟️🧱🍷
·1 t sittenOr you could have written it without being influenced by happy powder: "Circio has an interesting platform with promising preclinical data and is valued low compared to some of Big Pharma's latest acquisitions. It provides asymmetric upside if they continue to deliver. But we are still preclinical, and the road to a big deal or acquisition is long and uncertain. It requires both technical progress and timing."
Alle minuutti sittenAlle minuutti sittenInteresting perspective! I partly agree with you — but what he is doing is probably necessary. He and his team (and other trolls here⛄️) know this game very well. It is almost like a drug or an addiction that constantly needs a new supply of information, regardless of the quality or whether the content becomes repetitive. I am part of this feed too — most of us are. His posts may provide some sense of “psychological safety,” and emotions are processed somewhere in the brain, whether in the amygdala, prefrontal cortex, anterior cingulate cortex, or hippocampus — it does not really matter. 😅🤣 The outcome is still the outcome. However, my real question is this: what percentage of the “owners” in the attached picture actually read every post? I would genuinely be interested in seeing the IT statistics behind how much of this content is actually being processed and engaged with in this forum. And then we wonder why the needle may not necessarily move even a heartbeat 💓- 2 t sitten · Muokattu2 t sitten · MuokattuEli Lilly and Company isn't buying drugs. They're buying the delivery system for the next generation of medicine. Every single acquisition solves the same problem: how do you get a genetic therapy into the right tissue, without a virus, at scale, affordably? That's not a pipeline play. That's an infrastructure bet. I worked in pharma data long enough to know the difference between a company filling a revenue gap and a company rebuilding its entire platform. Revenue-gap buyers grab late-stage assets with near-term cash flow. Platform builders buy preclinical technology nobody else values yet. Lilly is doing the second thing. Seven times in a row. RNA is the new small molecule. Circular RNA, mRNA, DNA - Lilly is assembling every variant. They're not betting on one modality. They're betting on programmable medicine as a category.
Yllä olevat kommentit ovat peräisin Nordnetin sosiaalisen verkoston Nordnet Socialin käyttäjiltä, eikä niitä ole muokattu eikä Nordnet ole tarkastanut niitä etukäteen. Ne eivät tarkoita, että Nordnet tarjoaisi sijoitusneuvoja tai sijoitussuosituksia. Nordnet ei ota vastuuta kommenteista.
Uutiset
Tämän sivun uutiset ja/tai sijoitussuositukset tai otteet niistä sekä niihin liittyvät linkit ovat mainitun tahon tuottamia ja toimittamia. Nordnet ei ole osallistunut materiaalin laatimiseen, eikä ole tarkistanut sen sisältöä tai tehnyt sisältöön muutoksia. Lue lisää sijoitussuosituksista.
2025 Q4 -tulosraportti
Vain PDF
38 päivää sitten
Uutiset
Tämän sivun uutiset ja/tai sijoitussuositukset tai otteet niistä sekä niihin liittyvät linkit ovat mainitun tahon tuottamia ja toimittamia. Nordnet ei ole osallistunut materiaalin laatimiseen, eikä ole tarkistanut sen sisältöä tai tehnyt sisältöön muutoksia. Lue lisää sijoitussuosituksista.
Foorumi
Liity keskusteluun Nordnet Socialissa
Kirjaudu
- ·56 min sittenSomething I've been wondering about is that there are no recommendations from the analysts on the platform, does anyone have a thought about that?
- ·2 t sittenThe news is positive because the new patent application to the EPO concerns a genetic component that, according to Circio, increases the efficiency of circVec-based circRNA production by approx. 4 times. The company believes the technology can improve gene expression in gene therapy, among other things through more efficient use of AAV-based delivery systems. This is positive because patent/IP is extremely important in biotech. If Circio actually gets protection around a key component in circVec, it can strengthen their negotiating position against larger pharmaceutical companies. What seems most interesting right now is not just the patent news in isolation, but the combination of several potential triggers such as a new EPO application + planned global PCT application that can give the market more faith in the technology. Circio has announced that a feasibility study with a large global pharmaceutical company is moving on to in vivo testing. That is a more important trigger than just the patent news. They raised approx. NOK 68.6 million in Q1 2026 and had NOK 42 million in cash as of March 31, 2026. The company itself states that they are financed until at least 2030, which reduces short-term fear of equity issues, although biotech can always need more money later. The big point the market is probably following now is the warrants. Circio has 67,680,945 warrants with an exercise price of NOK 8.2508, with an exercise period from May 26 to June 9, 2026. Since the share is trading above the strike level, this can lead to both increased volatility and potential dilution, while also being able to provide the company with new capital. The next few weeks could be extra important for the development of the case. It will be particularly interesting to follow any partner news, results from in vivo testing, new patent updates, and upcoming webcast/presentation points from the company. At the same time, it is important to be aware of the risk factors around the warrant period, including possible selling pressure if many choose to exercise their warrants, any signals of new equity issues, and how volume and market interest develop.·3 min sittenWhat do you think the price will go higher this period warrants the shares can be bought? No one will buy these shares if the price doesn't become much higher than where we are now because then the risk or the price isn't worth them so if Erik and the gang want us to buy these warrants the price must rise or they won't get this warrants money
- ·2 t sittenCIRCIO IS A SMALL FISH. THAT IS THE POINT. 🧬🔬 Market cap today: approx. 2 billion NOK. That is approximately 185 million dollars. Let that sink in. A company with technology that shows 60x better expression than conventional AAV. That has Big Pharma involved in the in vivo study. That has Acuitas – the partners behind the Pfizer vaccine – on the team. That presented at the world's largest gene therapy conference. That operates in a field where Big Pharma has spent 14+ billion dollars on acquisitions in the last year. Valued at 185 million dollars. A single licensing agreement could be larger than the entire market cap. That's not a boast. That's mathematics. And here's what people forget: this is normally not available to you and me. Orna, Orbital, Capstan – all private. All bought for billions. No ordinary shareholders got to participate. Circio is the exception. Is there risk? Absolutely. This is preclinical biotech. But risk alone means nothing without context. Risk in a field where Big Pharma is desperately buying platforms. With technology that is starting to show mechanism. With partner-validated in vivo progress. With multiple shots on goal – AAV, LNP, CAR-T, heart, eye, CNS. A 10x from here is not a dream. It's a scenario that actually has a logical path there. We know what we own. ♟️🧱🍷·1 t sittenOr you could have written it without being influenced by happy powder: "Circio has an interesting platform with promising preclinical data and is valued low compared to some of Big Pharma's latest acquisitions. It provides asymmetric upside if they continue to deliver. But we are still preclinical, and the road to a big deal or acquisition is long and uncertain. It requires both technical progress and timing."Alle minuutti sittenAlle minuutti sittenInteresting perspective! I partly agree with you — but what he is doing is probably necessary. He and his team (and other trolls here⛄️) know this game very well. It is almost like a drug or an addiction that constantly needs a new supply of information, regardless of the quality or whether the content becomes repetitive. I am part of this feed too — most of us are. His posts may provide some sense of “psychological safety,” and emotions are processed somewhere in the brain, whether in the amygdala, prefrontal cortex, anterior cingulate cortex, or hippocampus — it does not really matter. 😅🤣 The outcome is still the outcome. However, my real question is this: what percentage of the “owners” in the attached picture actually read every post? I would genuinely be interested in seeing the IT statistics behind how much of this content is actually being processed and engaged with in this forum. And then we wonder why the needle may not necessarily move even a heartbeat 💓
- 2 t sitten · Muokattu2 t sitten · MuokattuEli Lilly and Company isn't buying drugs. They're buying the delivery system for the next generation of medicine. Every single acquisition solves the same problem: how do you get a genetic therapy into the right tissue, without a virus, at scale, affordably? That's not a pipeline play. That's an infrastructure bet. I worked in pharma data long enough to know the difference between a company filling a revenue gap and a company rebuilding its entire platform. Revenue-gap buyers grab late-stage assets with near-term cash flow. Platform builders buy preclinical technology nobody else values yet. Lilly is doing the second thing. Seven times in a row. RNA is the new small molecule. Circular RNA, mRNA, DNA - Lilly is assembling every variant. They're not betting on one modality. They're betting on programmable medicine as a category.
Yllä olevat kommentit ovat peräisin Nordnetin sosiaalisen verkoston Nordnet Socialin käyttäjiltä, eikä niitä ole muokattu eikä Nordnet ole tarkastanut niitä etukäteen. Ne eivät tarkoita, että Nordnet tarjoaisi sijoitusneuvoja tai sijoitussuosituksia. Nordnet ei ota vastuuta kommenteista.
Tarjoustasot
Oslo Børs
Määrä
Osto
-
Myynti
Määrä
-
Viimeisimmät kaupat
| Aika | Hinta | Määrä | Ostaja | Myyjä |
|---|---|---|---|---|
| 4 953 | - | - | ||
| 7 618 | - | - | ||
| 784 | - | - | ||
| 357 | - | - | ||
| 33 323 | - | - |
Huomioi, että vaikka osakkeisiin säästäminen on pitkällä aikavälillä tuottanut hyvin, tulevasta tuotosta ei ole takeita. On olemassa riski, että et saa sijoittamiasi varoja takaisin.
Välittäjätilasto
Dataa ei löytynyt
Asiakkaat katsoivat myös
Yhtiötapahtumat
Datan lähde: FactSet, Quartr| Seuraava tapahtuma | |
|---|---|
2026 Q2 -tulosraportti 31.8. |
| Menneet tapahtumat | ||
|---|---|---|
2025 Q4 -tulosraportti 15.4. | ||
2025 Q2 -tulosraportti 28.8.2025 | ||
2024 Q4 -tulosraportti 10.4.2025 | ||
2024 Q2 -tulosraportti 29.8.2024 | ||
2023 Q4 -tulosraportti 25.4.2024 |
2025 Q4 -tulosraportti
Vain PDF
38 päivää sitten
Uutiset
Tämän sivun uutiset ja/tai sijoitussuositukset tai otteet niistä sekä niihin liittyvät linkit ovat mainitun tahon tuottamia ja toimittamia. Nordnet ei ole osallistunut materiaalin laatimiseen, eikä ole tarkistanut sen sisältöä tai tehnyt sisältöön muutoksia. Lue lisää sijoitussuosituksista.
Yhtiötapahtumat
Datan lähde: FactSet, Quartr| Seuraava tapahtuma | |
|---|---|
2026 Q2 -tulosraportti 31.8. |
| Menneet tapahtumat | ||
|---|---|---|
2025 Q4 -tulosraportti 15.4. | ||
2025 Q2 -tulosraportti 28.8.2025 | ||
2024 Q4 -tulosraportti 10.4.2025 | ||
2024 Q2 -tulosraportti 29.8.2024 | ||
2023 Q4 -tulosraportti 25.4.2024 |
Foorumi
Liity keskusteluun Nordnet Socialissa
Kirjaudu
- ·56 min sittenSomething I've been wondering about is that there are no recommendations from the analysts on the platform, does anyone have a thought about that?
- ·2 t sittenThe news is positive because the new patent application to the EPO concerns a genetic component that, according to Circio, increases the efficiency of circVec-based circRNA production by approx. 4 times. The company believes the technology can improve gene expression in gene therapy, among other things through more efficient use of AAV-based delivery systems. This is positive because patent/IP is extremely important in biotech. If Circio actually gets protection around a key component in circVec, it can strengthen their negotiating position against larger pharmaceutical companies. What seems most interesting right now is not just the patent news in isolation, but the combination of several potential triggers such as a new EPO application + planned global PCT application that can give the market more faith in the technology. Circio has announced that a feasibility study with a large global pharmaceutical company is moving on to in vivo testing. That is a more important trigger than just the patent news. They raised approx. NOK 68.6 million in Q1 2026 and had NOK 42 million in cash as of March 31, 2026. The company itself states that they are financed until at least 2030, which reduces short-term fear of equity issues, although biotech can always need more money later. The big point the market is probably following now is the warrants. Circio has 67,680,945 warrants with an exercise price of NOK 8.2508, with an exercise period from May 26 to June 9, 2026. Since the share is trading above the strike level, this can lead to both increased volatility and potential dilution, while also being able to provide the company with new capital. The next few weeks could be extra important for the development of the case. It will be particularly interesting to follow any partner news, results from in vivo testing, new patent updates, and upcoming webcast/presentation points from the company. At the same time, it is important to be aware of the risk factors around the warrant period, including possible selling pressure if many choose to exercise their warrants, any signals of new equity issues, and how volume and market interest develop.·3 min sittenWhat do you think the price will go higher this period warrants the shares can be bought? No one will buy these shares if the price doesn't become much higher than where we are now because then the risk or the price isn't worth them so if Erik and the gang want us to buy these warrants the price must rise or they won't get this warrants money
- ·2 t sittenCIRCIO IS A SMALL FISH. THAT IS THE POINT. 🧬🔬 Market cap today: approx. 2 billion NOK. That is approximately 185 million dollars. Let that sink in. A company with technology that shows 60x better expression than conventional AAV. That has Big Pharma involved in the in vivo study. That has Acuitas – the partners behind the Pfizer vaccine – on the team. That presented at the world's largest gene therapy conference. That operates in a field where Big Pharma has spent 14+ billion dollars on acquisitions in the last year. Valued at 185 million dollars. A single licensing agreement could be larger than the entire market cap. That's not a boast. That's mathematics. And here's what people forget: this is normally not available to you and me. Orna, Orbital, Capstan – all private. All bought for billions. No ordinary shareholders got to participate. Circio is the exception. Is there risk? Absolutely. This is preclinical biotech. But risk alone means nothing without context. Risk in a field where Big Pharma is desperately buying platforms. With technology that is starting to show mechanism. With partner-validated in vivo progress. With multiple shots on goal – AAV, LNP, CAR-T, heart, eye, CNS. A 10x from here is not a dream. It's a scenario that actually has a logical path there. We know what we own. ♟️🧱🍷·1 t sittenOr you could have written it without being influenced by happy powder: "Circio has an interesting platform with promising preclinical data and is valued low compared to some of Big Pharma's latest acquisitions. It provides asymmetric upside if they continue to deliver. But we are still preclinical, and the road to a big deal or acquisition is long and uncertain. It requires both technical progress and timing."Alle minuutti sittenAlle minuutti sittenInteresting perspective! I partly agree with you — but what he is doing is probably necessary. He and his team (and other trolls here⛄️) know this game very well. It is almost like a drug or an addiction that constantly needs a new supply of information, regardless of the quality or whether the content becomes repetitive. I am part of this feed too — most of us are. His posts may provide some sense of “psychological safety,” and emotions are processed somewhere in the brain, whether in the amygdala, prefrontal cortex, anterior cingulate cortex, or hippocampus — it does not really matter. 😅🤣 The outcome is still the outcome. However, my real question is this: what percentage of the “owners” in the attached picture actually read every post? I would genuinely be interested in seeing the IT statistics behind how much of this content is actually being processed and engaged with in this forum. And then we wonder why the needle may not necessarily move even a heartbeat 💓
- 2 t sitten · Muokattu2 t sitten · MuokattuEli Lilly and Company isn't buying drugs. They're buying the delivery system for the next generation of medicine. Every single acquisition solves the same problem: how do you get a genetic therapy into the right tissue, without a virus, at scale, affordably? That's not a pipeline play. That's an infrastructure bet. I worked in pharma data long enough to know the difference between a company filling a revenue gap and a company rebuilding its entire platform. Revenue-gap buyers grab late-stage assets with near-term cash flow. Platform builders buy preclinical technology nobody else values yet. Lilly is doing the second thing. Seven times in a row. RNA is the new small molecule. Circular RNA, mRNA, DNA - Lilly is assembling every variant. They're not betting on one modality. They're betting on programmable medicine as a category.
Yllä olevat kommentit ovat peräisin Nordnetin sosiaalisen verkoston Nordnet Socialin käyttäjiltä, eikä niitä ole muokattu eikä Nordnet ole tarkastanut niitä etukäteen. Ne eivät tarkoita, että Nordnet tarjoaisi sijoitusneuvoja tai sijoitussuosituksia. Nordnet ei ota vastuuta kommenteista.
Tarjoustasot
Oslo Børs
Määrä
Osto
-
Myynti
Määrä
-
Viimeisimmät kaupat
| Aika | Hinta | Määrä | Ostaja | Myyjä |
|---|---|---|---|---|
| 4 953 | - | - | ||
| 7 618 | - | - | ||
| 784 | - | - | ||
| 357 | - | - | ||
| 33 323 | - | - |
Huomioi, että vaikka osakkeisiin säästäminen on pitkällä aikavälillä tuottanut hyvin, tulevasta tuotosta ei ole takeita. On olemassa riski, että et saa sijoittamiasi varoja takaisin.
Välittäjätilasto
Dataa ei löytynyt